Prostate Cancer Clinical Trial
— SPAOfficial title:
Stereotactic Prostate Radiotherapy With or Without Androgen Deprivation Therapy, a Phase III, Multi-institutional Randomized-controlled Trial. The SPA Trial.
To clarify the role of short-term Androgen deprivation therapy (ADT) in the context of intermediate unfavorable and a subclass of high-risk patients treated with prostate Stereotactic radiotherapy (SRT). In intermediate unfavorable risk group, when choosing standard external beam radiotherapy, short term ADT is superior in terms of biochemical disease free survival (bDFS) to EBRT alone. In high risk disease, results of the combination therapy are even more clear. Prostate SRT has been endorsed as option for primary radical treatment for prostate cancer. In such patients, the benefit of ADT is still unknown and the decision is left to clinical judgement. For these reasons, it seems to be relevant to propose a randomized, open label, phase III clinical trial of prostate SBRT + 6 months ADT versus prostate SBRT alone in intermediate unfavorable and a subgroup of high risk prostate cancer patients.
Status | Recruiting |
Enrollment | 310 |
Est. completion date | December 1, 2029 |
Est. primary completion date | December 1, 2025 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Histological confirmation of prostate acinar adenocarcinoma with a minimum of 10 biopsy cores taken - Prostate protocol MRI for local staging - Patients belonging to intermediate unfavorable group according to the D'Amico/NCCN risk group classification: - -Grade group 3 or/and - -2-3 risk factors for intermediate category (PSA 10-20 ng/ml/ Grade group 2-3/ cT2b cT2c) or/and - -biopsy cores positive =50% - Patients belonging to a subclass of high risk group according to the D'Amico/NCCN risk group classification: - -ISUP group 4 (GS 4+4, 3+5, 5+3) or - -cT3a stage or - PSA>20 - Eastern Coooperative Oncology Group (ECOG) PS 0-2 - Ability of the patient to understand and sign a written informed consent document - Ability and willingness to comply with patients reported outcome questionnaires schedule during the study time - IPSS 0-15 - Prostate Volume less than 100cc - PSA must be dosed maximum 60 days before randomization - No pathologic lymph nodes and distant metastasis on PET (fluorocholine) scan or CT scan+bone scan. - Contraceptive measures for patients with partners with reproductive potential must be explained Exclusion Criteria: - History of Malignant tumors in the previous 2 years excluding non melanoma cancers of the skin. If a patient presents an anamnesis of malignancy (excluding non melanoma skin cancers) it must be free from disease since 24 months at the time of enrollement. - Previous prostate surgery other than TURP (at least 6 weeks prior to start of SBRT). - Previous pelvic RT - Prior androgen deprivation therapy (excluding 5alpha reductase inhibitors) - Any prior active treatment for prostate cancer; patients on previous active surveillance are eligible if inclusion criteria are met - Active severe inflammatory bowel disease - Bilateral hip prothesis or any implant that could seriously interfere with dosimetric calculations - Age >80 years. - cT4a, cT3b or pelvic lymph node involvement - Controindication or hypersensitivity to the use of Triptoreline - 5alpha reductase inhibitors not discontinued 4 weeks prior to randomization - History of bone fractures and fall - Risk factors for abnormal heart rhythms or QT prolongation. - Use of concomitant medications that prolong the QT/QTc interval |
Country | Name | City | State |
---|---|---|---|
Italy | ASST Spedali Civili of Brescia | Brescia | BS |
Lead Sponsor | Collaborator |
---|---|
Marco Lorenzo Bonu | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | biochemical disease free survival | form the date of the end of radiotherapy to the date of PSA meeting protocol criteria for biochemical relapse or last Follow-up visit. Outcome is mesured in months. | outcome will be evaluated at the completion of 5 years of follow-up | |
Secondary | Disease free survival | from the date of the end of radiotherapy to the date of relapse (any) or last Follow-up visit.Outcome is mesured in months. | outcome will be evaluated at the completion of 5 years of follow-up | |
Secondary | freedom from local recurrence | from the date of the end of radiotherapy to the date of local relapse or last Follow-up visit. Outcome is mesured in months. | outcome will be evaluated at the completion of 5 years of follow-up | |
Secondary | freedom from regional recurrence | from the date of the end of radiotherapy to the date of regional relapse or last Follow-up visit. Outcome is mesured in months. | outcome will be evaluated at the completion of 5 years of follow-up | |
Secondary | freedom from distant metastasis | from the date of the end of radiotherapy to the date of metastatic relapse or last Follow-up visit. Outcome is mesured in months. | outcome will be evaluated at the completion of 5 years of follow-up | |
Secondary | Overall survival | from the date of the end of radiotherapy to the date of death 8any cause) or last Follow-up visit. Outcome is mesured in months. | outcome will be evaluated at the completion of 5 years of follow-up | |
Secondary | quality of life, prostate related quality of life in prostate cancer | scored with questionnaire Expandend Prostate cancer Index Composite-26 (EPIC-26), score scale is 0-100 with higher scores representing better health related quality of life | 12 weeks after SRT, 3, 6 and 12 months after SRT | |
Secondary | quality of life, prostate related quality of life questionnarire | scored with questionnaire European organization for research and treatment of cancer PR 25, (EORTC PR 25), All of the scales and single-item measures range in score from 0 to 100. A high score for the Sexual Activity and Sexual Functioning scales represents a high level of functioning, whereas a high score for the Urinary, Bowel, and Hormonal Treatment Related symptoms scales and Incontinence Aid item represents a high level of symptomatology or problems. | 12 weeks after SRT, 3, 6 and 12 months after SRT | |
Secondary | patients reported outcome, erectile function assessment, | scored with questionnaire International Index of Erectile Function 5 (IIEF from 25 (best) to 5 (worse)) | 12 weeks after SRT, 3, 6 and 12 months after SRT | |
Secondary | patients reported outcome, prostate related symptoms assessment | scored with questionnaire Internation Prostate syntoms scale (IPSS, from 0 (best) to 35 (worse)) | 12 weeks after SRT, 3, 6 and 12 months after SRT | |
Secondary | Clinician reported Acute Toxicity, assessed with CTCAE 5.0 scales | Outcome is mesured in 0-5 scale (higher scale worse toxicity) | from the beginning of treatment until 6 months after SRT | |
Secondary | Clinician reported Late Toxicity, assessed with CTCAE 5.0 scales | Outcome is mesured in 0-5 scale (higher scale worse toxicity) | from 6 months after SRT 5 years of follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Active, not recruiting |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |